• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Charging Robotics Inc
Citic Ltd Ord
Sflmaven Corp
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

295.54 -2.96 (-0.99%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 164,511
Open 297.67
Bid (Size) 226.18 (100)
Ask (Size) 351.89 (200)
Prev. Close 298.50
Today's Range 292.56 - 297.67
52wk Range 175.89 - 326.63
Shares Outstanding 16,676,532
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup Caution ↗
September 28, 2026
Via Chartmill
News headline image
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today ↗
September 02, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals... 
Via Benzinga

Performance

52-Week Range 9.5% below 52-week high
295.54
175.8952W Low 326.6352W High
1 Week 5.2% below 1-week high
292.281W Low 311.861W High

Ligand Pharmaceuticals Incorporated - Common Stock (LGND) traded between $175.89 and $326.63 over the past 52 weeks and last traded at $295.54, 9.5% below its 52-week high. Over the past week it ranged between $292.28 and $311.86.

Past 12 Months
-5.0%
+7.4%
-2.6%
+27.5%
+55.5%
+63.5%
1W -$15.59
1M +$20.34
3M -$7.85
6M +$63.72
YTD +$105.43
1Y +$114.77

LGND was +63.5% over the past year, +27.5% over six months, +55.5% year to date, -5.0% in the last week.

12 Months vs Market
LGND
+63.5%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months LGND returned +63.5% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 0.65× 3-mo avg
Today 164,511 3-mo avg 251.7K
1W
223.6K
1M
273.1K
3M
251.7K
6M
293.1K
YTD
270.5K
1Y
257.3K

LGND most recently traded 164,511 shares against a 3-month average daily volume of 251.7K.

More News

Read More
News headline image
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital ↗
August 26, 2026
Via MarketBeat
News headline image
$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today ↗
August 21, 2026
Via Benzinga
News headline image
Ligand (LGND) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings
Ligand Pharmaceuticals (NASDAQ:LGND) Beats Q2 EPS Estimates, Shares Flat on In-Line Revenue ↗
August 06, 2026
Via Chartmill
News headline image
Ligand Pharmaceuticals Q2 Earnings Call Highlights ↗
August 06, 2026
Via MarketBeat
Topics Earnings
News headline image
$100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
August 05, 2026
Via Benzinga
News headline image
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
July 14, 2026
From Ligand Pharmaceuticals
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Its Acquisition by Ligand
July 14, 2026
From XOMA Royalty Corporation
Via GlobeNewswire
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Fall on Q1 Revenue and EPS Miss ↗
May 07, 2026
Via Chartmill
News headline image
3 Overlooked Stocks Positioned for the Next Market Rotation ↗
July 13, 2026
Via MarketBeat
Topics Artificial Intelligence
News headline image
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned? ↗
June 14, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million ↗
June 07, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Wealth Manager Sells $7 Million of Establishment Labs After Massive Gains. Is This Medical Device Stock a Buy? ↗
May 30, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
OneSpaWorld Posted Record Revenue for Last Quarter. Why Did a Fund Exit a $21.5 Million Stake? ↗
May 29, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Genpact Stock a Buy After Hedge Fund Rice Hall James Raised Its Stake by $14 Million? ↗
May 19, 2026
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Is WaterBridge Stock a Buy After Ranger Investment Raised Its Stake by 345,000 Shares? ↗
May 16, 2026
Via The Motley Fool
Topics Initial Public Offering
News headline image
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
May 12, 2026
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Ligand (LGND) Q1 2026 Earnings Call Transcript ↗
May 12, 2026
Via The Motley Fool
Topics Earnings
News headline image
Ligand Pharmaceuticals Q1 Earnings Call Highlights ↗
May 08, 2026
Via MarketBeat
Topics Earnings
News headline image
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
May 06, 2026
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
May 05, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing ↗
May 04, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 Million ↗
May 02, 2026
Via The Motley Fool
Topics Energy Regulatory Compliance

Frequently Asked Questions

Is Ligand Pharmaceuticals Incorporated - Common Stock publicly traded?
Yes, Ligand Pharmaceuticals Incorporated - Common Stock is publicly traded.
What exchange does Ligand Pharmaceuticals Incorporated - Common Stock trade on?
Ligand Pharmaceuticals Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ligand Pharmaceuticals Incorporated - Common Stock?
The ticker symbol for Ligand Pharmaceuticals Incorporated - Common Stock is LGND on the Nasdaq Stock Market
What is the current price of Ligand Pharmaceuticals Incorporated - Common Stock?
The current price of Ligand Pharmaceuticals Incorporated - Common Stock is 295.54
When was Ligand Pharmaceuticals Incorporated - Common Stock last traded?
The last trade of Ligand Pharmaceuticals Incorporated - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Ligand Pharmaceuticals Incorporated - Common Stock?
The market capitalization of Ligand Pharmaceuticals Incorporated - Common Stock is 4.93B
How many shares of Ligand Pharmaceuticals Incorporated - Common Stock are outstanding?
Ligand Pharmaceuticals Incorporated - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap